Area of research
Physiology · Molecular Biology
Research interest
Research interests include Alzheimer's disease research and treatments, Neuroscience and Neuropharmacology Research, Autophagy in Disease and Therapy, and Ubiquitin and proteasome pathways.
Molecular mechanisms of mitochondrial quality control
LCN2 induces neuronal loss and facilitates sepsis-associated cognitive impairments
Age-related p53 SUMOylation accelerates senescence and tau pathology in Alzheimer’s disease
Nicotine Reprograms Aging‐Related Metabolism and Protects Against Motor Decline in Mice
Ppp2r1a haploinsufficiency increases excitatory synaptic transmission and decreases spatial learning by impairing endocannabinoid signaling
Aging-dependent YAP1 reduction contributes to AD pathology by upregulating the Nr4a1-AKT/GSK-3β axis
<scp>ApoE4</scp> Upregulates <scp>GSK</scp> ‐3β to Aggravate Alzheimer‐Like Pathologies and Cognitive Impairment in Type 2 Diabetic Mice
Improving vulnerable Calbindin1− neurons in the ventral hippocampus rescues tau-induced impairment of episodic memory
Age-dependent elevation of Nr4a1 attenuates PI3K/AKT/GSK3β pathway and mediates tau hyperphosphorylation and cognitive impairments
Long Term High‐Salt Diet Induces Cognitive Impairments via Down‐Regulating SHANK1
Cryptic Splicing of <i>GAP43</i> mRNA is a Novel Hallmark of TDP‐43‐Associated ALS and AD
Updates in Alzheimer's disease: from basic research to diagnosis and therapies
A positive feedback inhibition of isocitrate dehydrogenase 3β on paired-box gene 6 promotes Alzheimer-like pathology
Abnormal protein post-translational modifications induces aggregation and abnormal deposition of protein, mediating neurodegenerative diseases
Generation of tau dephosphorylation-targeting chimeras for the treatment of Alzheimer’s disease and related tauopathies
A new tau dephosphorylation-targeting chimera for the treatment of tauopathies
Targeting vulnerable microcircuits in the ventral hippocampus of male transgenic mice to rescue Alzheimer-like social memory loss
Development of tau phosphorylation-targeting therapies for the treatment of neurodegenerative diseases
Social isolation impairs cognition via Aβ-mediated synaptic dysfunction
EPO Deficiency Upregulates GADD45b/p38 MAPK Axis, Mediating Schizophrenia‐Related Synaptic and Cognitive Impairments
Correction: A positive feedback inhibition of isocitrate dehydrogenase 3β on paired-box gene 6 promotes Alzheimer-like pathology
Conformation pattern changes in R1-pS262 tau peptide induced endogenous tau aggregation, synaptic damage, and cognitive impairments
Ferulic Acid Improves Synaptic Plasticity and Cognitive Impairments by Alleviating the PP2B/DARPP-32/PP1 Axis-Mediated STEP Increase and Aβ Burden in Alzheimer's Disease
Targeting a vulnerable septum-hippocampus cholinergic circuit in a critical time window ameliorates tau-impaired memory consolidation
A novel transgenic mouse line with hippocampus-dominant and inducible expression of truncated human tau
<scp>GSK</scp>‐3β activation mediates apolipoprotein <scp>E4</scp>‐associated cognitive impairment in type 2 diabetes mellitus: A multicenter, cross‐sectional study
Gypenoside IX restores Akt/GSK-3β pathway and alleviates Alzheimer’s disease-like neuropathology and cognitive deficits
C9orf72 <scp>poly‐PR</scp> helps p53 escape from the ubiquitin‐proteasome system and promotes its stability
Single‐nucleus transcriptome profiling of prefrontal cortex induced by chronic methamphetamine treatment
c-Src regulates δ-secretase activation and truncated Tau production by phosphorylating the E3 ligase Traf6